Literature DB >> 24191316

Oxidative stress and total antioxidant status in acute leukemia at diagnosis and post remission induction phase.

Arshi Naz1, Tahir S Shamsi, Abdul Sattar, Tabassum Mahboob.   

Abstract

This study evaluated the activity of superoxide dismutase (SOD1), glutathione reductase (GR) and total antioxidant status (TAS) in the hemolysate and sera of patients with acute leukemia (AL) at diagnosis, post remission induction phase and in healthy controls. However, total antioxidant status and glutathione reductase activities normalized after remission induction phase in acute myeloid leukemia (AML) only whereas levels of SOD were reduced but not achieved the normal level in acute lymphoblastic leukemia (ALL). TAS activity showed no difference in either sex among any subtype of acute leukemia but glutathione reductase level was significantly higher in female ALL patients. Activity of SOD was elevated in T-cell ALL and acute myelomonocytic leukemia however; no significant difference in the activity of GR and TAS was noted. Levels of antioxidant were reduced insignificantly in patients who achieved complete remission.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24191316

Source DB:  PubMed          Journal:  Pak J Pharm Sci        ISSN: 1011-601X            Impact factor:   0.684


  2 in total

1.  Impact of the induction phase chemotherapy on cytokines and oxidative markers in peripheral and bone marrow plasma of children with acute lymphocytic leukemia.

Authors:  G E Broto; P R B Silva; F C Trigo; V J Victorino; K L Bonifácio; W R Pavanelli; F Tomiotto-Pelissier; M R Garbim; S T Oliveira; J J Jumes; C Panis; D S Barbosa
Journal:  Curr Res Immunol       Date:  2021-10-08

2.  From Six Gene Polymorphisms of the Antioxidant System, Only GPX Pro198Leu and GSTP1 Ile105Val Modulate the Risk of Acute Myeloid Leukemia.

Authors:  Claudia Bănescu; Mihaela Iancu; Adrian P Trifa; Marcela Cândea; Erzsebet Benedek Lazar; Valeriu G Moldovan; Carmen Duicu; Florin Tripon; Andrei Crauciuc; Minodora Dobreanu
Journal:  Oxid Med Cell Longev       Date:  2015-12-28       Impact factor: 6.543

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.